EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

What should clinic procurement teams do now?

Dose Diligence research deskSection 04 · Page 1 of 17Last updated 17 Nov 2026

Do not renew a GLP-1 supply arrangement on the strength of shortage-era permissions, a pharmacy licence, or a supplier’s promise of “personalisation.” Our procurement recommendation is to approve the exact product, physical facility, destination state and intended use before comparing price. FDA registration does not establish that an outsourcing facility’s products qualify for the statutory exemptions, and a patient-specific prescription does not satisfy every condition of section 503A. FDA registration explanation; section 503A. (fda.gov)

The most consequential developments are not all prohibitions. They include stronger scrutiny of compounded-product documentation, appellate decisions supporting FDA’s shortage determinations, new safety communications, an extended DSCSA exemption for qualifying small dispensers, and a Medicare access programme that changes the patient-cost comparison. The table below identifies the operational decisions each development affects.

Evidence boundary: this report distinguishes statutes, court decisions, enforcement positions, proposals and analyst recommendations. FDA’s dynamic shortage-detail pages could not be retrieved successfully during this review; the shortage discussion therefore relies on FDA’s published policy and determination documents, supplemented by the appellate opinions. Obtain a fresh shortage-status record before any transaction that depends on shortage status. This is decision support, not legal advice or product-specific clearance.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
  2. uscode.house.gov · Source 2 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration?utm_source=openai
Section sources →